iBio, Inc. (IBIO)
Stock Price:
$1.49 USD
-0.02 (-1.32%)
Updated November 30, 4:00 PM EST - Market closed
Pre-market: $1.46 -0.03 (-2.01%) Dec 1, 4:06 AM
Key Info
| Market Cap |
271.34M |
| Revenue (ttm) |
1.94M |
| Net Income (ttm) |
-41.33M |
| Shares Out |
182.11M |
| EPS (ttm) |
-0.42 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 30 |
| Last Price |
$1.49 |
| Previous Close |
$1.51 |
| Change ($) |
-0.02 |
| Change (%) |
-1.32% |
| Day's Open |
1.48 |
| Day's Range |
1.43 - 1.51 |
| Day's Volume |
7,019,700 |
| 52-Week Range |
0.19 - 6.41 |
More Stats
| Market Cap |
271.34M |
| Enterprise Value |
220.62M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
182.11M |
| Float |
n/a |
| EPS (basic) |
-0.67 |
| EPS (diluted) |
-0.42 |
| FCF / Share |
-0.12 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
12.71M |
| Short Ratio |
2.11 |
| Short % of Float |
n/a |
| Beta |
-5.94 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
139.87 |
| PB Ratio |
3.32 |
| Revenue |
1.94M |
| Operating Income |
-17.07M |
| Net Income |
-41.33M |
| Free Cash Flow |
-19.84M |
| Net Cash |
50.72M |
| Net Cash / Share |
0.28 |
| Gross Margin |
84.43% |
| Operating Margin |
-880.00% |
| Profit Margin |
-2,130.40% |
| FCF Margin |
-1,022.42% |
| ROA |
-14.00% |
| ROE |
-49.97% |
| ROIC |
-27.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
2.00
Current: $1.49
High
2.00
Target: 2.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 1.64 | 2.02 | 0.44 | 0.39 | 0.95 | 1.85 | 0.21 | 1.01 | 1.28 | 0.52 |
| Revenue Growth | -18.83% | 354.5% | 12.69% | -58.44% | -48.78% | 802.93% | -79.64% | -21.14% | 145.54% | - |
| Gross Profit | 1.64 | 2.02 | 0.44 | 0.39 | 0.95 | 1.85 | 0.21 | 1.01 | 1.28 | 0.52 |
| Operating Income | -14.00 | -15.79 | -14.23 | -14.27 | -9.89 | -6.67 | -3.84 | -6.67 | -9.33 | -9.65 |
| Net Income | -16.44 | -17.59 | -16.11 | -14.53 | -9.76 | -6.63 | -3.67 | -6.20 | -5.68 | -12.14 |
| Shares Outstanding | 62.80 | 18.93 | 10.63 | 8.91 | 8.10 | 7.15 | 6.30 | 4.94 | 3.95 | 3.10 |
| Earnings Per Share | -0.61 | -0.94 | -1.54 | -1.64 | -1.20 | -0.90 | -0.60 | -1.30 | -1.40 | -3.90 |
| Operating Cash Flow | -13.35 | -13.98 | -13.48 | -13.16 | -8.07 | -4.73 | -4.12 | -4.85 | -6.01 | -5.34 |
| Capital Expenditures | -1.15 | -0.99 | -1.08 | -1.59 | -0.07 | -0.22 | -0.26 | -0.20 | -0.25 | -0.09 |
| Free Cash Flow | -14.50 | -14.97 | -14.56 | -14.76 | -8.14 | -4.94 | -4.38 | -5.04 | -6.26 | -5.43 |
| Cash & Equivalents | 55.11 | 4.42 | 15.93 | 8.09 | 23.01 | 9.49 | 3.59 | 4.41 | 5.62 | 2.84 |
| Total Debt | 32.91 | 24.88 | 25.08 | 25.27 | 25.44 | - | - | - | - | - |
| Net Cash / Debt | 22.20 | -20.46 | -9.15 | -17.18 | -2.42 | 9.49 | 3.59 | 4.41 | 5.62 | 2.84 |
| Assets | 94.19 | 30.59 | 43.08 | 36.01 | 51.60 | 12.49 | 6.49 | 9.35 | 9.77 | 7.34 |
| Liabilities | 37.58 | 28.13 | 26.92 | 27.10 | 27.56 | 1.26 | 0.40 | 4.29 | 3.60 | 7.14 |
| Book Value | 56.62 | 2.46 | 16.17 | 8.91 | 9.94 | 11.23 | 6.10 | 5.07 | 6.17 | 0.20 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
iBio, Inc. |
| Country |
United States |
| Employees |
43 |
| CEO |
Thomas F. Isett |
Stock Information
| Ticker Symbol |
IBIO |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: IBIO |
Description
iBio, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.